These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32553611)

  • 41. Autoimmunity in systemic sclerosis: current concepts.
    Boin F; Rosen A
    Curr Rheumatol Rep; 2007 May; 9(2):165-72. PubMed ID: 17502048
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Systemic sclerosis-clinical picture, diagnosis, and treatment].
    Becker MO; Distler O; Maurer B
    Hautarzt; 2019 Sep; 70(9):723-741. PubMed ID: 31384958
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis.
    Meyer OC; Fertig N; Lucas M; Somogyi N; Medsger TA
    J Rheumatol; 2007 Jan; 34(1):104-9. PubMed ID: 17117486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Immunopathological disturbances in systemic sclerosis].
    Gindzieńska-Sieśkiewicz E; Klimiuk PA; Kowal-Bielecka O; Sierakowski S
    Pol Merkur Lekarski; 2005 Dec; 19(114):800-3. PubMed ID: 16521427
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges.
    Peltzer J; Aletti M; Frescaline N; Busson E; Lataillade JJ; Martinaud C
    Front Immunol; 2018; 9():2013. PubMed ID: 30271402
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic sclerosis and the gastrointestinal tract.
    Walecka I
    Prz Gastroenterol; 2017; 12(3):163-168. PubMed ID: 29123575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunological basis of systemic sclerosis.
    Zuber JP; Spertini F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii23-5. PubMed ID: 16987826
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Late onset systemic sclerosis with seronegativity: a rare presentation of an uncommon disease.
    Saxena D; Jain D; Yadav M; Giri K; Yadav T; Jain P
    Reumatismo; 2019 Oct; 71(3):166-170. PubMed ID: 31649382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise?
    Antic M; Distler JH; Distler O
    Curr Opin Pharmacol; 2013 Jun; 13(3):455-62. PubMed ID: 23747024
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression.
    Cavazzana I; Ceribelli A; Airo' P; Zingarelli S; Tincani A; Franceschini F
    Autoimmun Rev; 2009 Jun; 8(7):580-4. PubMed ID: 19393210
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Autoantibodies and their clinical characteristics in systemic sclerosis].
    Hamaguchi Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(3):139-47. PubMed ID: 23812071
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Systemic sclerosis-clinical picture, diagnosis, and treatment].
    Becker MO; Distler O; Maurer B
    Z Rheumatol; 2019 Jun; 78(5):439-457. PubMed ID: 31089800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exosomes in Systemic Sclerosis: Messengers Between Immune, Vascular and Fibrotic Components?
    Colletti M; Galardi A; De Santis M; Guidelli GM; Di Giannatale A; Di Luigi L; Antinozzi C
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31487964
    [No Abstract]   [Full Text] [Related]  

  • 54. The lung megakaryocytes and pulmonary fibrosis in systemic sclerosis.
    Thachil J
    Med Hypotheses; 2009 Mar; 72(3):291-3. PubMed ID: 19036527
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early systemic sclerosis-opportunities for treatment.
    Sakkas LI; Simopoulou T; Katsiari C; Bogdanos D; Chikanza IC
    Clin Rheumatol; 2015 Aug; 34(8):1327-31. PubMed ID: 25711876
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathophysiology of systemic sclerosis: current understanding and new insights.
    Cutolo M; Soldano S; Smith V
    Expert Rev Clin Immunol; 2019 Jul; 15(7):753-764. PubMed ID: 31046487
    [No Abstract]   [Full Text] [Related]  

  • 57. New pathogenic and therapeutic concepts in systemic sclerosis.
    Hügle T; Huigens CA; van Laar JM
    Arzneimittelforschung; 2009; 59(12):615-24. PubMed ID: 20108646
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis.
    Terras S; Hartenstein H; Höxtermann S; Gambichler T; Kreuter A
    Int J Dermatol; 2016 Aug; 55(8):882-5. PubMed ID: 26499848
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Strategy for treatment of fibrosis in systemic sclerosis: Present and future.
    Yanaba K
    J Dermatol; 2016 Jan; 43(1):46-55. PubMed ID: 26782006
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Classification criteria of scleroderma].
    Cabane J;
    Presse Med; 2006 Dec; 35(12 Pt 2):1916-22. PubMed ID: 17159717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.